{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T17:54:25Z","timestamp":1790099665041,"version":"4.0.1"},"reference-count":25,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2019,10,11]],"date-time":"2019-10-11T00:00:00Z","timestamp":1570752000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Cosmetic Dermatology"],"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Melasma is an acquired disorder of facial pigmentation which is a treatment challenge.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aims<\/jats:title><jats:p>The aim of this article is to critically appraise the clinical trial evidence for different treatment modalities for melasma, published in peer\u2010reviewed journals in the past 10\u00a0years.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients\/Methods<\/jats:title><jats:p>The literature review was conducted using PubMed and MEDLINE. The search was performed in July 2019, and search parameters were limited to all English language articles published in the past 10\u00a0years only.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Eighty\u2010nine clinical trials were found. Four clinical trials investigated topical hydroquinone, supporting its safety and efficacy as first\u2010line treatment. Twelve studies showed tranexamic acid as very promising. Nineteen studies assessed various novel oral, injectable, and topical treatments and highlight some new potential future treatments. Forty\u2010two studies investigated laser and light treatment in melasma: LFQS laser is still one of the best options, especially in darker skin types. However, the picosecond laser has shown excellent results. Finally, 11 studies looked at peels. Overall, peels have not been shown to be superior to the use of topical therapy alone.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Topical therapy with a HQ and retinoid\u2010based product should be first line for a minimum of 3\u00a0months with the addition of oral tranexamic acid at 250\u00a0mg BD if no contraindication. Second\u2010line treatment with lasers includes the LFQS Nd:YAG, picosecond laser, and the pulsed dye laser in lighter skin types. Third\u2010line therapy would be the addition of chemical peels to the above treatments, with GA or TCA peels having the most evidence for effectiveness.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jocd.13182","type":"journal-article","created":{"date-parts":[[2019,10,11]],"date-time":"2019-10-11T10:54:22Z","timestamp":1570791262000},"page":"1284-1289","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Melasma: A critical analysis of clinical trials investigating treatment modalities published in the past 10\u00a0years"],"prefix":"10.1111","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2772-2017","authenticated-orcid":false,"given":"Natalia M. K.","family":"Spierings","sequence":"first","affiliation":[{"name":"Dermatology Queen Mary University of London London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,10,11]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yacs.2018.02.008"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijwd.2017.11.003"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijwd.2018.09.004"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2010.95"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2018.12.008"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546630903341945"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.02.009"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijwd.2017.01.004"},{"key":"e_1_2_6_10_1","unstructured":"Group OLoEW.The Oxford levels of evidence 2.https:\/\/www.cebm.net\/index.aspx?o=5653"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-015-0292-8"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1473-2165.2011.00580.x"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2012.04464.x"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.03.001"},{"issue":"8","key":"e_1_2_6_15_1","first-page":"732","article-title":"A split\u2010face, double\u2010blind, randomized and placebo\u2010controlled pilot evaluation of a novel oligopeptide for the treatment of recalcitrant melasma","volume":"8","author":"Hantash BM","year":"2009","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13424"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2017.1351608"},{"issue":"9","key":"e_1_2_6_18_1","first-page":"1025","article-title":"A comparative study of the safety and efficacy of 75% mulberry (Morus alba) extract oil versus placebo as a topical treatment for melasma: a randomized, single\u2010blind, placebo\u2010controlled trial","volume":"10","author":"Alvin G","year":"2011","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"e_1_2_6_19_1","first-page":"67","article-title":"Comparison between Intralesional Triamcinolone and Kligman's formula in treatment of melasma","volume":"54","author":"Eshghi G","year":"2016","journal-title":"Acta Med Iran"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctcp.2015.10.004"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/lsm.22735"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/14764172.2017.1376098"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10103-018-2529-2"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2011.255"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2014.5580"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.12195"}],"container-title":["Journal of Cosmetic Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jocd.13182","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jocd.13182","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jocd.13182","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T12:35:15Z","timestamp":1693744515000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jocd.13182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,11]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["10.1111\/jocd.13182"],"URL":"https:\/\/doi.org\/10.1111\/jocd.13182","archive":["Portico"],"relation":{},"ISSN":["1473-2130","1473-2165"],"issn-type":[{"value":"1473-2130","type":"print"},{"value":"1473-2165","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,11]]},"assertion":[{"value":"2019-07-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-16","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}